Public-registry site landscape for NCT07730489, a Colorectal Cancer study sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07730489 (registry record) |
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Condition(s) | Colorectal Cancer |
| Phase | PHASE3 |
| Listed sites | 2 |
| Site countries | China |
At The First Hospital of China Medical University — one of the facilities listed on this trial — 44 other studies are actively recruiting Colorectal Cancer patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07730489 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →